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Atrial ﬁbrillation is the most common sustained arrhythmia and is associated with signiﬁcant risks of thromboembolism, stroke,
congestive heart failure, and death. There have been major advances in the management of atrial ﬁbrillation including pharmaco-
logic therapies, antithrombotic therapies, and ablation techniques. Surgery for atrial ﬁbrillation, including both concomitant and
stand-alone interventions, is an eﬀective therapy to restore sinus rhythm. Minimally invasive surgical ablation is an emerging ﬁeld
that aims for the superior results of the traditional Cox-Maze procedure through a less invasive operation with lower morbidity,
quicker recovery, and improved patient satisfaction. These novel techniques utilize endoscopic or minithoracotomy approaches
with various energy sources to achieve electrical isolation of the pulmonary veins in addition to other ablation lines. We review
advancements in minimally invasive techniques for atrial ﬁbrillation surgery, including management of the left atrial appendage.
1.Introduction
Atrial ﬁbrillation (AF) is the most common cardiac arrhyth-
mia, aﬀecting over 2 million people in the United States [1].
The lifetime risks for developing AF are 1 in 6, even in those
without previous cardiac disease and as high as 1 in 4 in
those individuals older than 40 years [2]. It is associated with
nearly a ﬁve-fold increased risk of stroke and over two-fold
increase risk of death [3]. There have been many advances
in the management of AF including pharmacological ther-
apies, antithrombotic therapies, and ablation techniques.
Concurrently, minimally invasive cardiac surgery techniques
have emerged to treat selected patients with AF, refractory
to medical therapy, with surgical ablation and left atrial
appendage (LAA) resection through much smaller, sternal
sparing incisions. These innovative techniques focus on
pulmonary vein isolation, ablation of the left atrial isthmus
and right atrial isthmus in addition to other ablation lines
and can be performed as either a stand-alone operation or
concomitant with another minimally invasive cardiac opera-
tion. The goals of minimally invasive AF surgeries are to
achieve the same success in restoring sinus rhythm as the
conventional Cox-Maze procedure with a more cosmetically
appealing incision, quicker recovery, and improved patient,
satisfaction.
2. History of AF Surgery
It hasbeen recognized that in patients with chronic AF, phar-
macological rhythm control is ineﬀective in half of patients,
and electrical cardioversion has high recurrence rates [4, 5].
As a result, surgical ablation techniques were developed
overthepast30yearstoaddressmedicallyrefractorypatients
with few other options. In 1980, Williams and coworkers
developed an arrhythmia procedure which isolated the left
atrium electrically from the remainder of the heart to
conﬁne AF to the left atrium [6]. In 1990, Guiraudon and
coworkers described a more aggressive technique, the Corri-
dor procedure [7], which created an isolated strip of muscle
connecting the sinus node to atrioventricular node. These
two procedures had some eﬀect to restore sinus rhythm;2 ISRN Cardiology
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Figure 1: Lesion sets. (a): traditional Cox-maze III operation, (b): Cryomaze procedure, (c): commonly employed epicardial radiofrequency
ablation. The solid lines indicate the “cut and sew” incisions, and the broken lines indicate the ablation lines. MV: mitral valve, TV: tricuspid
valve, IVC: inferior vena cava, SVC: superior vena cava, LAA: left atrial appendage, LSPV: left superior pulmonary vein, LIPV: left inferior
pulmonary vein, RSPV: right superior pulmonary vein, and RIPV: right inferior pulmonary vein.
however, the shortcomings of these two procedures were
continued ﬁbrillation of both atria with persistent risk of
thromboembolism and lack of atrial transport function.
In1991,CoxandcoworkersreportedtheMazeprocedure
based on experimental and early clinical evidence [8]. The
Maze operation consisted of several atrial disconnections
(“cut and sew”) to create lines of electrical block for pulmo-
nary vein isolation and interruption of all potential macro-
reentrantcircuits.TheMazeprocedurewasmodiﬁedtwiceto
improve the left atrial transport function and to simplify the
operation (Cox-Maze II and III). In 1996, they reported the
seriesof118patientsundergoingtheCox-MazeIIIprocedure
(Figure 1(a)), which achieved an operative mortality of 2%,
freedom from AF was 93% in the mean followup of 8.5 years
[9].
Although the Cox-maze III procedure was eﬀective, it
was not widely adopted because of its overall complexity and
invasiveness. In late 1990s, radiofrequency, cryoablation, and
other energy sources were developed to simplify the “cut
and sew” technique. In 1998, Ha¨ ıssaguerre and coworkers
reported a landmark study that suggested that AF originated
from ectopic beats within the pulmonary veins [10]w h i c h
further conﬁrmed the rationale behind the maze procedure.
Since then, AF surgery continues to focus on left atrial isola-
tion but has been progressing towards more complete lesion
sets with minimally invasive techniques to allow optimal
treatment of AF through less invasive methods. Patients con-
tinue to demand more eﬀective and less invasive therapies,
particularly in cases of lone atrial ﬁbrillation.
3.Development of Minimally
InvasiveAFSurgery
Minimally invasive techniques were introduced to cardiac
surgery in the mid-1990s, with the blending of reduced
incision sizes, sternal-sparing minithoracotomy approaches,
endoscopic visualization, and modiﬁed cardiopulmonary
bypass techniques to enable safe and eﬀective, less invasiveISRN Cardiology 3
valve surgery [11–13]. Over the past decade, alternative
energy sources have been developed for arrhythmia surgery
thathavefacilitatedaparadigmshifttowardsminimallyinva-
sive AF ablation surgery. As we outline further ahead, there
are many diﬀerent general approaches, incisions, energy
sources, lesion sets, and perfusion strategies that have been
described as “minimally invasive.” There remains no clear
consensusonwhatdeterminesanoperationtobe“minimally
invasive,”asmostdeﬁnitionsfocusonthepotentialimproved
outcomes, rather than the procedural details themselves. In
general with regards to minimally invasive AF operations,
surgicalinvasivenessandoperativeeﬃcacymaybesomewhat
inverselyproportional,wheretheidealminimallyinvasiveAF
operation oﬀers a patient the least “invasiveness” with max-
imal eﬃcacy which will certainly vary based upon AF char-
acteristics, duration of AF, left atrial size, and other patient
related factors. In this paper, we deﬁne minimally invasive
AF surgery as those approaches that employ smaller, sternal-
sparing incisions using less invasive alternative energy
sources with or without cardiopulmonary bypass.
4.AlternativeEnergySources
Ablation techniques are dependent on the ability to create
electrical conduction blocks within the heart to interrupt
all potential macroreentrant circuits. The classic method in
surgery to create conduction block has been the “cut and
sew” technique (Figure 1(a)). It has been the most reliable
method for creating transmural lesions that block atrial
conduction; however, is also associated with signiﬁcant risks
of hemorrhage and prolonged aortic cross clamp times.
Over the past decade, there has been signiﬁcant progress
in the development of alternative ablative devices with diﬀer-
ent energy sources that are safer alternatives to the “cut and
sew” technique. In order to creation transmural atrial lesions
to block electrical conduction, tissue must be subjected
to either hypothermic (<−60◦C) or hyperthermic (>50◦C)
damage. Hypothermic energy is delivered by cryothermy,
while hyperthermic energies include radiofrequency (RF),
microwave, ultrasound, and laser. The ideal energy source
would create well-demarcated, transmural lesions through
either epicardial or endocardial application with a quick,
cost-eﬀective device that can be utilized minimally invasively
and does not encourage endocardial thrombus formation.
We will review commonly utilized energy sources and high-
light speciﬁc advantages and disadvantages.
4.1. Cryothermy. Cryothermy was the ﬁrst energy source to
be used in arrhythmia surgery and was one of the most
common alternative and additive energy sources to the “cut
andsew”method.Cryothermyusesargonwhichachievestis-
s u et e m p e r a t u r e so f−150◦C or nitrous oxide which achieves
temperatures of −60◦C. The main advantages of cryothermy
are the ability to create long lesion lines with modern ﬂexible
probes and the ability to mimic the entire lesion set of the
Cox-maze III operation [14, 15]. In fact, the original Cox-
maze procedure included cryothermy of the left atrial isth-
mus and a tissue gap under the left atrial appendage [8, 9].
Cryothermy has several other potential advantages in-
cluding less risk of endocardial thrombus [16, 17] and lower
risk of collateral damage to surrounding structures such as
mitral leaﬂet tissue, the circumﬂex coronary artery, the coro-
narysinus,ortheesophagus[17–19].Themaindisadvantage
of cryothermy is its poor eﬃcacy during oﬀ pump or beating
heart procedures from an epicardial approach because the
warming eﬀect of endocardial blood ﬂow [14, 15, 19, 20].
Another disadvantage is the ablative time requirement of 60–
120secondsforfreezingandthesubsequenttimeforthawing
to reposition the probe.
4.2. Radiofrequency (RF). RF is a simple and eﬀective energy
source that has been widely used in catheter-based ablation.
TheapplicationofRFenergyincreasesthetissuetemperature
to 50–55◦C with consequent coagulation and permanent
destruction of cell structure and collagen [17, 21]. Available
RF surgical devices include irrigated or dry application, and
unipolar or bipolar systems. The addition of irrigation is
believed to allow for the creation of deeper and theoretically
more complete lesion lines.
Unipolar devices are usually ﬂexible probes that allow
lesion creation in ﬂat and angulated areas; however, lesion
gaps can be more common. Bipolar RF devices commonly
have a “C clamp” shape, where the energy source is delivered
between the electrodes mounted between both jaws of the
clamp. Advantages of bipolar RF over unipolar RF are ability
to make quick lesion sets (approximately 10 seconds), direc-
tional energy delivery, with theoretically less risk of collateral
tissue damage, and determination of transmurality with
impedance monitoring. Bipolar RF devices have been widely
accepted as a safe and eﬀective ablation for pulmonary vein
isolation in minimally invasive AF surgery [21].
The main disadvantage of RF is the risk of intracavity
thrombus formation. In fact, RF is considered the most
thrombogenic energy source, with reports of embolic com-
plications with coil-tipped catheters [22]. Collateral tissue
damage with esophageal perforation and left circumﬂex
artery injury has been reported as well [17, 23, 24]. Careful
placementofbipolarRFdevices,ratherthanunipolar,should
help to minimize these risks. Bipolar RF devices are generally
notusedtocreatetheconnectinglesiontothemitralannulus
because injurious risks to the circumﬂex artery and mitral
leaﬂet tissue.
4.3. Microwave. Microwave generates heat by causing vibra-
tion and rotation of water molecules. These devices consist
of a generator system and an antenna mounted on a shielded
shaft to deliver microwaves to the site of ablation [17, 25–
27]. The duration of application is usually 60–120 seconds.
Wisser and coworkers found similar results when comparing
microwave and RF ablations when performing the Cox-maze
III procedure [25]. At the 12 months, freedom from AF was
81% and 80% in the microwave and RF groups, respectively.
Topkaraandcoworkersreportedsimilarﬁndingsinperform-
ing a lesion set similar to the Cox-maze III, with freedom
from AF of 66% and 71% in microwave and RF ablation,
respectively [26].4 ISRN Cardiology
Advantages of microwave technology are lower risks
of thromboembolism, minimal char formation, and the
creation of a well-demarcated area of the thermal injury.
Microwave is not only capable of producing transmural
lesions when applied to the epicardial surface but also may
avoid collateral damage because excess energy is absorbed by
bloodelements.Furthermore,themicrowaveprobe(Flex-10,
AFX Inc, Fremont, CA, USA) is ﬂexible and long, making it
amenable to minimally invasive techniques. Microwave was
theﬁrstenergysourcetobeusedinthoracoscopicAFsurgery
[27]. Although complications are rare, the epicardial con-
necting lesion to mitral valve annulus is avoided because of
concerns of circumﬂex coronary artery intimal damage [28].
4.4. Laser. Laser ablation uses high-energy optical waves to
create a narrow, deep, and well-demarcated lesion with min-
imal lateral expansion from both endocardial and epicaridal
approach [17, 29]. Animal studies have demonstrated that
laser ablation is able to produce rapid, histologically trans-
mural lesions capable of electrically isolating the atrium.
The tissue is ablated by direct heating to relatively low
temperatures (50◦C) and also by mechanical damage from
cellularlysiscausedbyshock waves.HammanandTheologes
reported left-sided lesion sets with laser ablation in patients
with paroxysmal AF and biatrial lesion sets in those with
persistent or permanent AF with an overall 76% freedom
from AF up to 18 months [29].
4.5. Ultrasound. High-intensity focused ultrasound (HIFU)
uses acoustic energy to create a hyperthermic transmural
lesions. Its theoretical advantage is its proposed ability to
create deeper and hypothetically more complete lesions than
other energy sources. HIFU is capable of producing trans-
mural lesions from an epicardial approach, in short period
of time (less than 2 seconds) [17, 30].
Ninet and coworkers have reported the initial clinical
experience with HIFU in a multicenter trial [30]. An epi-
cardial ablation was performed on the beating heart before
undergoing the concomitant procedure in 103 patients with
either permanent (74%), paroxysmal (21%), or persistent
(5%) AF. All patients underwent pulmonary vein isolation
(boxlesion),andanadditionalmitrallinewascreatedepicar-
dially in 34%. At the 6-month period, freedom from AF was
85% in the entire study group. Unfortunately, a case of fatal
atrioesophagealﬁstulawasreportedat31dayspostoperative-
ly [31]. Because of issues of limited experience and diﬃculty
using the bulky device, HIFU has not gained widespread
acceptance for treatment of atrial ﬁbrillation.
5.MinimallyInvasiveApproaches
Haissaguerre’sworkwithectopicbeatswithinthepulmonary
veins has spurred the growth of catheter-based ablation tech-
niques for AF [10]. At present, it remains the least invasive
treatment for AF; however, catheter based approaches often
requiremorethanoneprocedureandhaveconsiderablerisks
of recurrent AF, especially in patients with persistent AF [32–
34]. Miyazaki et al. have reported that during 30 months
of followup after the initial ablation, 59% of patients with
persistent AF were free of atrial tachyarrhythmia [33].
Pokushalov et al. have reported that 12-month freedom from
AF after catheter ablation for persistent AF was 48% after
1 ablation procedure and 64% after 1 or more procedures
[34]. These ﬁndings continue to encourage the growth of
surgical ablation techniques to develop less invasive but
moreeﬀectivealternatives.Arrhythmiasurgeryhasalsofaced
the same less invasive trends as other conventional cardiac
operations. Sternal-sparing, direct vision minithoracotomy,
endoscopic and robotic approaches have been developed to
treat both lone AF and more commonly as concomitant
therapy with mitral valve disease. These minimally invasive
techniques seek to achieve the same very high standards of
the Cox-maze operation with lower risks, less morbidity,
quicker recovery, and improved patient satisfaction. The
development of minimally invasive AF surgery has been
basedontwofactors:moresimpliﬁedandtargetedlesionsets
andtheintroductionofthepreviouslymentionedspecialized
ablation devices to replace the traditional “cut and sew”
maze procedure. Epicardial ablative devices have allowed for
the evolution of oﬀ-pump, thoracoscopic approaches. The
hallmark lesion set of minimally invasive AF surgery still
remains pulmonary vein isolation. However, recent advances
in thoracoscopic approaches have allowed for the expansion
ofmorecomplexlesionsetstoimprovepatientresults.Right-
sided lesions, autonomic denervation, left atrial appendec-
tomy in addition to concomitant valvular surgery can all be
performed simultaneously, further enhancing the strength
and utility of these minimally invasive approaches.
6.MinimallyInvasiveCryomaze Procedure
The biatrial Cryomaze procedure utilizes cryotherapy to
replicate all of the original Cox-maze III lesion sets, without
the same invasiveness and bleeding risks (Figure 1(b))[ 35–
38]. Results with the Cryomaze procedure have demon-
strated eﬃc a c yf o rb o t hp a r o x y s m a la n dp e r m a n e n tA F[ 15,
36, 37]. In fact in patients with permanent AF, the Cryomaze
procedure has provided comparable maintenance of sinus
rhythmwithlesscross-clamptimeandbleedingcomparedto
the traditional “cut and sew” maze procedure [38]. Freedom
from AF after the Cryomaze procedure is reported to be 60–
80% at postoperative 3 years [15, 36].
The Cryomaze can be performed endoscopically, roboti-
cally or through a 3-4cm right minithoracotomy using car-
diopulmonary bypass with femoro-femoral cannulations
and right jugular venous cannulation (Figures 2(a) and 2(b))
[35, 37]. The CryoCath ablation system (Medtronic Inc.,
MN, USA) uses argon to cool tissue to as low as −160◦C.
The system is well suited to a minimally invasive technique
because it is a ﬂexible, linear probe available in lengths of
6–10cm. The minimally invasive Cryomaze procedure has
alsodemonstratedexcellentresultsintheloneAFpopulation
[37]. A total of 41 patients with lone AF underwent a mini-
mally invasive, biatrial Cryomaze with no deaths or strokes.
At discharge and 6 weeks postoperatively, 36 (87.8%) and
37 (90.2%) patients were in sinus rhythm, respectively. At
later followup, sinus rhythm was present in 93% (38/41) atISRN Cardiology 5
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Figure 2: (a) intraoperative view of minimally invasive concomitant mitral valve repair and Cryomaze procedure. The argon-based ﬂexible,
linear ablation probe is applied through a 3cm right minithoracotomy. (b) intraoperative view of minimally invasive, videoscopic Cryomaze
setup.
(a) (b)
Figure 3: Operative setup for minimally invasive biatrial Cryomaze procedure with concomitant mitral valve repair. (a): intraoperative
patient positioning, (b): 2 months postoperative result.
3 months, 87% (34/39) at 6 months, and 87% (20/23) at one
year [37].
The biatrial Cryomaze procedure is our preferred
method of surgical treatment for atrial ﬁbrillation. We treat
patients with symptomatic paroxysmal or permanent AF
with a duration <10 years, left atrial size <6.5cm, who have
strong motivations to be anticoagulation free. Most patients
that we treat also have concomitant mitral valve disease that
requires surgical intervention. We employ videoscopic assis-
tance to perform the operation through a 3-4cm right mini-
thoracotomy with peripheral cannulation (Figures 2 and 3).
Following the ablation, prior to the mitral valve repair, we
generally perform a left atrial appendectomy by invaginat-
ing, excising, and oversewing the stump of the left atrial
appendage from within the left atrium. We have experienced
good success rates with freedom from recurrent atrial
ﬁbrillation >90% and 80% in patients with paroxysmal and
persistent AF, respectively.
7. MinimallyInvasiveRadiofrequency
Maze Procedure
Minimally invasive AF surgery with RF ablation techniques
can be performed with unipolar or bipolar devices. Most
approaches have focused on epicardial pulmonary vein
ablation alone with “clamp” bipolar devices around the pul-
monary veins (Figure 1(c)); however, more complex lesion
sets have also been added with unipolar RF or adjunct cry-
oablation.6 ISRN Cardiology
In 2002, Damiano and Gaynor described the Cox-maze
IV procedure using bipolar RF through standard sternotomy
and cardiopulmonary bypass [39]. In this procedure, a
bipolar RF clamp was used to create conduction block in
most of the atrial lines; however, linear cryoablation was still
required for mitral and tricuspid valve annuli in the vast
majority cases. In 2010, the same group described the mini-
mally invasive Cox-maze IV procedure through a right
mini-thoracotomy with cardiopulmonary bypass, peripheral
cannulation, and aortic cross clamping [40]. This procedure
mimics the open Cox-maze IV lesion set, performed through
direct vision and minithoracotomy. The freedom from AF in
22 patients was 94% and 81% without antiarrhythmic med-
ications at 6 and 12 months, respectively. In 2011, Damiano
and coworkers reported series of 282 patients undergoing
Cox-maze IV procedure since 2002 (42% paroxysmal and
58% persistent AF) [41]. The freedom from atrial ﬁbrillation
was 93% and 89% at 6 and 12 months, respectively. The free-
dom from both atrial ﬁbrillation and antiarrhythmic drugs
was 79% and 78% at 6 and 12 months, respectively.
In 2004, Sie and coworkers reported an RF-based maze
procedure with similar lesion set to Cox-maze IV as an
adjunct to open heart surgery under cardiopulmonary
bypass and cross clamp [42, 43]. The diﬀerence from Cox-
maze IV was that they created only endocardial linear abla-
tion lines using unipolar irrigated RF. They reported 44-
month follow-up results of their RF-based maze in 258
patients with structural heart disease and permanent AF
[44]. Sustained sinus rhythm, including atrial rhythm or an
atrial-based paced rhythm was present in 69% of patients at
1 year, in 56% at 3 years, and in 52% at 5 years.
Kiserandcoworkersdescribedatotallyextracardiacmaze
(Ex-Maze) procedure which closely mimics the Cox-maze III
lesion set by using vacuum-integrated radiofrequency abla-
tiondeviceonthebeatingheart[45].TheExMazeprocedure
was performed during 44 concomitant cardiac procedures
for patients with AF; of these, 82% of the patients had
persistent or permanent AF. Freedom from AF was 66% and
79% at postoperative 1 month and 3 month, respectively.
8.BilateralVideo-Assisted
Thoracoscopic AF Surgery
In 2005, Wolf and coworkers reported their initial experience
with bilateral video-assisted thoracoscopic AF surgery [21].
Pulmonary vein isolation was achieved through bilateral
minithoracotomy incisions and using a dry RF bipolar
device. The left atrial appendage was removed with a surgical
stapler.FreedomfromAFwas91%at3-monthfollowup.Ina
subsequent study of 157 patients with up to 4-year followup,
they reported a cure rate for paroxysmal AF of 92%, for
persistent AF, 85%, and for chronic AF, 75%. Although this
technique requires bilateral anterolateral thoracotomies, it
has several proposed advantages including (1) lack of cardio-
pulmonary bypass, (2) exclusion of left appendage, and (3)
bilateral autonomic denervation can be performed simulta-
neously.
Beyer and coworkers performed a multicenter study
of 100 patients with atrial ﬁbrillation (39 paroxysmal, 29
persistent,and32permanent)usingtheWolftechnique[46].
The mean operative time was 253 minutes, and the mean
length of stay was 6.5 days. Results demonstrated an 86%
overall success rate (93% paroxysmal, 96% persistent, and
71% permanent), with 62% discontinuation of antiarrhyth-
mic drugs, and 65% discontinuation of anticoagulation.
However, there was a 13% rate of complication (pacemaker
implantation, phrenic nerve injury, postoperative hemotho-
rax, and transient ischemic attack) over a mean follow-up
time of 14 months.
9.Robot-AssistedMinimally
InvasiveAFSurgery
Loulmet and colleagues ﬁrst described oﬀ-pump robotic
endoscopic pulmonary vein isolation with microwave energy
(FLEX 10, Boston Scientiﬁc Corp., Natick, MA, USA) in a
patient in chronic AF in 2004 [47]. Bolotin and coworkers
were the ﬁrst to describe using the da Vinci robot and micro-
wave ablation to treat concomitant AF and mitral valve dis-
ease [48]. The same group (Chitwood) reported the results
of combined robotic mitral repair and microwave ablation
techniques in a series of 16 patients, where 73% were in sinus
rhythm 6 months after operation. The microwave ablation
probewasintroducedthrougha4cmrightminithoracotomy
to perform epicardial and endocardial pulmonary vein isola-
tion with cardiopulmonary bypass. The da Vinci robot was
used to manipulate and position the probe as well as closing
the left atrial appendage and repairing the mitral valve [49].
One patient underwent emergent stenting of the left circum-
ﬂex artery for coronary injury secondary to the microwave
ablation. More recently, Cheema and coworkers have de-
scribed a technique of robotic, endoscopic, and on-pump
beating heart left atrial cryoablation; however, further results
are awaited [50].
10. Totally Endoscopic AF Surgery for Lone AF
Saltman and coworkers ﬁrst reported a totally endoscopic
microwaveablationprocedureusing3accessportsbilaterally
for paroxysmal AF in 2003 [27]. They later reported a series
of 30 patients (50% paroxysmal) with this minimally inva-
sive, purely endoscopic approach [51]. Results suggested a
freedom from AF after 12 months of 58% overall, with 70%
freedom from AF in patients with paroxysmal disease. There
were no deaths in this series; however, minor morbidities
were encountered in 16%, ranging from pneumonia to left
atrial appendage injury requiring conversion to open thora-
cotomy.
In 2007, Pruitt and colleagues reported a series of 100
cases of bilateral thoracoscopic microwave ablation; 64%
paroxysmal, 11% persistent, and 25% permanent [52]. Un-
fortunately, their results only achieved a 42% freedom form
AFatmeanfollowupof23months.Mortalityatlastfollowup
was 3%. In 9% of patients, the thoracoscopic box pulmonary
vein isolation and subsequent electrophysiological inter-
vention failed, and a Cox-maze operation was successfully
performed. Yilmaz and coworkers reported completely tho-
racoscopic pulmonary vein isolation with ganglionic plexusISRN Cardiology 7
ablation and left atrial appendage amputation using bipolar
RF ablation [53, 54]. In their study, AF was paroxysmal in
63%, persistent in 27%, and permanent in 10% of cases.
FreedomfromAFwasobtainedin77%ofthepatientsduring
a mean followup of 12 months. Edgerton has described a
series of patients undergoing bilateral endoscopic ablation
with a more comprehensive lesion set, claiming to mimic the
Cox-maze III operation [55]. They reported good results in
an initial series of 74 patients with 84% and 57% freedom
from AF in patients with paroxysmal or longstanding
persistent AF at 6-month followup, respectively.
11.Concomitant MinimallyInvasive
AF Surgery and Mitral Valve Surgery
Minimally invasive techniques within cardiac surgery were
ﬁrst applied to mitral valve surgery [12, 13]; however,
because of common surgical exposures, similar minimally
invasive options were rapidly developed for AF surgery with
theaimofreducingmorbidity,postoperativepain,andblood
loss[56].Sincemitralvalvediseaseoftenpresentswithahigh
prevalenceofAF,therewasthenaturalprogressiontofurther
develop concomitant minimally invasive therapies to address
both disease processes simultaneously. Both endocardial and
epicardial approaches have been utilized in addition to
multiple energy sources [49, 50].
In 2006, Akpinar and coworkers reported the results of a
randomized trial in which 67 patients with permanent AF
undergoing minithoracotomy mitral valve surgery with or
without AF ablation with unipolar endocardial RF (Cardio-
blate, Medtronic Corp., Minneapolis, MN, USA) [57]. The
pulmonary veins were isolated as pairs, and a lesion was then
placed to the mitral valve annulus. Freedom from AF in the
ablated group was signiﬁcantly higher than that in the con-
trol group at 1-year followup (94% versus 9%; P = 0.0001).
Jeanmartandcoworkersdemonstratedamodiﬁedmazewith
unipolarRFconcomitantwithminithoracotomymitralvalve
surgeryresultedin70%freedomfromAFatameanfollowup
of 17 months [58]. Gillinov and Svensson have developed an
approach for creation of biatrial lesion sets for AF ablation
with mitral valve surgery through a transseptal exposure and
partial upper sternotomy [59].
12.MinimallyInvasiveAF Surgeryversus
Catheter Abaltion
Catheter ablation is the least invasive procedure for patients
with AF refractory to antiarrhythmic medication; however,
high recurrence rate for persistent AF remains problematic
[33, 34]. In contrast, minimal invasive surgical ablation may
bemoreeﬀectiveandcanincludevarioustypesofprocedures
such as pulmonary vein isolation, LAA excision, and ganglia
ablation; however, it is still more invasive requiring general
anesthesiaandathoracotomycomparedtocatheterablation.
Atrial ﬁbrillation catheter ablation versus surgical abla-
tion treatment (FAST) trial is a randomized clinical trial
comparing their eﬃcacy and safety [60]. One hundred
twenty-four patients with antiarrhythmic drug-refractory
atrial ﬁbrillation were randomized to catheter ablation (63
patients) or surgical ablation (61 patients). Catheter ablation
consisted of linear atrial pulmonary vein isolation and
optional additional lines. Surgicalablation consisted of bipo-
lar RF isolation of the pulmonary veins, ganglionated plexi
ablation, and left atrial appendage excision with optional
additional lines [60, 61]. Freedom from any left atrial
arrhythmia >30 seconds after 12 months was 36.5% for
catheter ablation and 65.6% for surgical ablation (P =
0.0022). However, the adverse events related with procedural
complications was signiﬁcantly higher for surgical ablation
than for catheter ablation during the 12-month followup
(34.4% versus 15.9%; P = 0.027).
13.HybridApproach:Minimally
InvasiveSurgicalAblationwith
EPCatheterApproach
A hybrid procedure of minimally invasive AF surgery and
combined electrophysiology (EP) mapping and ablation has
recently been introduced to overcome the shortcomings
of each technique individually [62, 63]. In this technique,
AF ablation through a minithoracotomy is performed with
concomitant EP mapping to conﬁrm conduction block
along these lesion sets. Additional surgical and percutaneous
ablationisperformedtoachievecompleteblockasnecessary.
Advantages of the hybrid procedure are (1) to conﬁrm
conduction block, (2) to maximize eﬃcacy of AF ablation
and outcomes, and (3) to minimize potential complications
of catheter ablation such as lesion gaps, tamponade, and
thrombus formation. This technique does require the exper-
tise and resources of both the surgical and EP teams working
together; however, these cases are more time consuming.
This technique was ﬁrst reported in 2007 as combined
procedure with epicardial left atrial ablation and percuta-
neous endocardial ablation in diﬃcult cases of AF [63].
In 2011, Krul and coworkers reported thoracoscopic video-
assisted pulmonary vein antrum isolation, ganglionated
plexus ablation, and periprocedural conﬁrmation of ablation
lesions for 31 patients (16 paroxysmal AF, 13 persistent AF,
and 2 longstanding persistent AF) [64]. Intraoperative EP
testing and additional ablation lesions were performed to
accomplish complete block. Freedom from AF/atrial ﬂutter/
atrial tachycardia without using antiarrhythmic drugs was
86%.
14. Left AtrialAppendage Management
Cerebral infarction is the most devastating complication of
AF. Blackshear reported that in patients with AF, left atrial
thrombi was most commonly found in the LAA in 91% of
nonvalvular AF and 57% of valvular AF [65]. Surgical oblit-
eration ofthe LAA is a conceptthatis widely acceptedduring
AF surgery; however, the best surgical method has not been
determined. Generally, the LAA has been approached
from both epicardial and endocardial methods. Epicardial
approaches have consisted of (1) excision and oversewing or
stapling or (2) proprietary “clip-like” devices. The excision8 ISRN Cardiology
technique conﬁrms removal of the part of the appendage,
however, can have risks of hemorrhage and potential throm-
bus formation in incompletely resected LAA with partial
remaining stumps. Epicardial approaches are best suited
towards bilateral thoracotomy approaches. Endocardial
approaches can be utilized most commonly with a right
minithoracotomy approach. Both purse-string and running
suture closure techniques (exclusion) have been employed
to obliterate the LAA ostium; however, these techniques
frequentlyfailbyallowingLAArecanalization[66,67].When
performing a right minithoracotomy approach (our most
common approach), we prefer invaginating the LAA into the
left atrium and excising and oversewing of the LAA to con-
ﬁrm elimination. This must be carefully performed to pre-
vent excessive blood losses and prior to concomitant mitral
valve repair, as the LAA suture line can be hard to secure
safely with a rigid annuloplasty ring in place.
The LAA occlusion study (LAAOS) randomized 77
sternotomy-based patients into occlusion group with suture
or stapler and control group [67]. In this study, prophylactic
LAA occlusion did not reduce the risk of neurological events.
Transesophageal echo (TEE) revealed that successful LAA
closure was obtained only in 43% in the suture closure
method versus 72% in the stapled group. The negative pri-
mary outcome in this study may have been secondary to
high failure rate of LAA closure or the small sample size.
Kanderian and coworkers reviewed 137 of 2546 patients
undergoing surgical LAA closure, who had TEE after surgery
by any reason [66]. Fifty-two patients (38%) had the exci-
sion, and 85 (62%) underwent exclusion (73 with suture and
12withastapler)oftheLAA.Althoughoverallsuccessfulclo-
sure was only 40%, the success rate was signiﬁcantly diﬀerent
among the groups; 73%, 23%, and 0% in excision, suture
exclusion, and stapler exclusion, respectively. LAA thrombus
was present in 41% of patients with unsuccessful LAA
exclusion versus 0% in the entire excision group. They con-
cluded the LAA excision was the most reliable method. The
other interesting ﬁnding from both LAAOS and Kanderian’s
report, the suture exclusion tended to fail due to persistent
ﬂow into the LAA, while stapled exclusion group tended to
fail due to the presence of a remnant appendage deﬁned as
larger than 1cm [66, 67].
Garcia-Fernandez and coworkers investigated 205
patients undergoing mitral valve surgery and compared 58
patients with LAA ligation and 147 patients without LAA
occlusion [68]. They reported that both incomplete LAA
occlusion and no LAA occlusion were major risk factors for
thromboembolism. Interestingly, they also suggested that
incompleteLAAocclusionwasmoredangerousthannoLAA
occlusion. In a review by Chatterjee and colleagues, they
reported that 7 of 10 studies with diﬀerent LAA occlusion
techniqueshadpositiveeﬀectonreducingstrokerisk;though
the success rate was highly dependent on the closure tech-
nique [69]. As a result, they recommended complete closure
of the LAA by excision and oversewing to ensure optimal
results. The most feared complication of LAA excision
remains hemorrhage, particularly in frail, elderly patients
with thin and fragile LAA. Pericardial reinforced techniques
may be one way to minimize bleeding risks [70].
IntermsofdrawbacksofLAAobliteration,thereareafew
reportsabouttheimpactofLAAexclusiononleftatrialfunc-
tion.Isobeandcoworkersdevelopedbilateralappendagepre-
serving maze procedure in 2001 [71]. They concluded that
thebilateralappendagepreservingmazeprocedureimproved
atrial transport and atrial natriuretic peptide secretion with-
out decreasing the eﬀectiveness of maze procedure against
AF. Kamohara and coworkers described that LAA exclusion
may aﬀect left atrial reservoir function in short- and mid-
term periods in animal models [72]. Yamanaka and cowork-
ers reported the inﬂuence of LAA exclusion on left atrial
function by computed tomography [73]. In their study, LAA
preservation contributed to improved transport function,
and none of their patients in sinus rhythm after the maze
procedure experienced a thromboembolic event.
Management of the left atrial appendage in minimally
invasive surgery varies depending on the surgical approaches
including bilateral mini-thoracotomy, right minithoracot-
omy, or percutaneous occlusion. Bilateral thoracotomy
approaches allow direct access to the left atrial appendage
and, henceforth, allows for all conventional techniques of
epicardial resection, stapling, or clip devices. The Wolf pro-
cedureallowsforstaplerresectionoftheLAAthroughtheleft
thoracotomy [61]. Recently, clip type LAA occlusion devices
have been developed for thoracoscopic approach. In 2010,
Salzbergetal.reportedLAAclipocclusionwith100%success
rate [74]. In right minithoracotomy approaches, commonly
utilized with concomitant mitral valve surgery, LAA exclu-
sion with purse-string or running sutures has been the most
common modality used. However, concerns of high fail-
ure rates and early recanalization have tempered these
approaches [67]. As a result, invagination of the left atrial
appendage into the body of the left atrium, excision and
direct suturing, as was performed in the original Cox-
maze operation is probably the most eﬃcacious method to
achieve complete LAA occlusion via this minimally invasive
approach.
Percutaneous transcatheter closure devices implanted
in the catherization lab are also currently available. Three
transcatheter devices have been developed: the Percutaneous
Left Atrial Appendage Transcatheter Occlusion (PLAATO)
d e v i c e( e V 3 ,P l y m o u t h ,M N ,U S A )[ 75], Watchman device
(AtritechInc.,Plymouth,MN,USA)[76],andtheAmplatzer
CardiacPlug(ACP)(ASO,AGAMedical/St.JudeMedical,St.
Paul, MN, USA) [77]. All three devices are constructed from
self-expandable nitinol frame and polymeric membrane.
They are delivered percutaneously through a transseptal
approach into the left atrium.
The PLAATO device was the ﬁrst device developed and
consists of a self-expandable nitinol cage with a polyte-
traﬂuoroethylene membrane [75]. It was studied in 111
patients with contraindications to oral anticoagulation and
demonstrated successful implantation rates of 97%. There
were six major adverse events, including one death and two
strokes during a mean followup of 9.8 months. The authors
r e p o r t e das t r o k er a t eo f2 . 2 % / y e a rc o m p a r e dw i t ht h e
estimated annual stroke rate of 6.3% (using CHADS2 score).
The Watchman device is a parachute-shaped device with
ﬁxation barbs for secure implantation within the LAA [76].ISRN Cardiology 9
The Watchman device is more ﬂexible than the PLAATO
device and has less need for oversizing in the LAA oriﬁce.
The Watchman Left Atrial Appendage System for Embolic
Protection in Patients with Atrial Fibrillation (PROTECT-
AF) trial evaluated the device in a prospective, randomized
design involving 707 nonvalvular patients with CHADS2
score ≥1[78].Thepatientswererandomizedtoreceiveeither
the LAA occlusion device or long-term warfarin therapy.
These trial results demonstrated the noninferiority of the
Watchman device compared with long-term warfarin ther-
apy group. In the Watchman group, there was a 38% reduc-
tion in primary eﬃcacy, 29% in stroke, and 38% in death
compared with the long-term warfarin therapy group. How-
ever, there was a 77% increase in primary safety events in the
Watchman group. Speciﬁcally, procedural/device complica-
tions occurred in 11% of the Watchman group: procedural
stroke 1%, device embolization 1%, signiﬁcant pericardial
eﬀusion 5%, and bleeding 4%. A recent analysis of the non-
randomized Continued Access Protocol registry including
460 subsequent patients after PROTECT-AF study demon-
strated a signiﬁcant improvement in device/procedure-
related complications of during the latter half of PROTECT-
AF study [78]: procedural stroke 0%, device embolization
0%, signiﬁcant pericardial eﬀusion 2%, and bleeding 1%.
This improved safety was attributed to increased operator
experience and device improvements.
The third available option is the Amplatzer Cardiac Plug
(ACP)device,whichconsistsofalobeforﬁxationintheLAA
and a disc for covering the mouth of the LAA like a paciﬁer.
Pilot study results have demonstrated successful device
implantation in 96% of patients, with serious complications
such as ischemic stroke, device embolization, and pericardial
eﬀusion observed in 7% [77]. A randomized trial is under-
way to assess the ACP device [79].
15. Qualityof Literature/FutureDevelopments
As the treatment of AF continues to evolve, so do minimally
invasive approaches to surgical ablation including the energy
sources, surgical approaches, and lesion sets. Current and
future therapies must be based upon good evidence to
ensure optimal patient outcomes; however, most research in
surgical therapies for AF consist of small case series or non-
randomized data with follow-up periods of less than 2 years.
As lesion sets and energy sources change frequently, there is a
direneedtoexerciserigorousrandomizedclinicaltrialdesign
to assess the eﬃcacy of these surgical techniques. Followup
must be complete and employ continuous event monitors
rather than most studies which rely upon the inaccuracies
of telephone followup and “spot” electrocardiograms. The
deﬁnition of recurrent AF following an ablation procedure
remainscontroversial(i.e.,adeﬁnedtimeperiodversusclini-
cally relevant outcomes associated with AF) and requires
strictdeﬁnitionpriortoembarkingonarandomized,clinical
trial [80]. Considering the high failure rates of left atrial
appendage ligation, patients should always be reassured of
complete left atrial appendage closure with an imaging
modality. Patient followup is essential to proving the true
worth of all ablation techniques. Ultimately, any ablation
technique will only be eﬃcacious if it reduces symptoms
andlatecomplicationsofstroke,congestiveheartfailure,and
death.
16. Summary
Surgical therapies for AF continue to evolve. Patient demand
for minimally invasive techniques will exponentially grow. In
the traditions of our surgical forefathers, we must continue
to innovate and reﬁne less invasive methods that focus on
providing the superior results of the Cox-maze procedure
with endoscopic approaches that facilitate quicker patient
recovery, faster healing, improved cosmetics, and overall
lower patient morbidity.
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